The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)
Official Title: A Phase II Single-group Assignment, Multicenter Study of Efficacy and Safety of Lorlatinib Monotherapy After Failure of First-line Tyrosine Kinase Inhibitor in Patients With Advanced ROS1-positive Non-small Cell Lung Cancer (ALBATROS)
Study ID: NCT04621188
Brief Summary: ROS1 rearrangements are present in 1-2% of NSCLC cases and define a distinct molecular subgroup. Like ALK (anaplastic lymphoma kinase) rearrangements in NSCLC, ROS1 fusions confer sensitivity to the inhibitor crizotinib. Crizotinib, which is a tyrosine kinase inhibitor (TKI), has been shown to be effective in tumors in several retrospective studies. Recently the FDA approved entrectinib for the treatment of patients with ROS1-positive metastatic NSCLC. This indication is based on the results of pooled data from several trials. Together, these studies demonstrate the efficacy for entrectinib across a variety of solid tumor types including NSCLC with ROS1 fusion. However, despite the efficacy of crizotinib or entrectinib in ROS1-positive NSCLC, patients will develop resistance to these tyrosine kinase inhibitors. Lorlatinib is a new and potent ROS1 / ALK inhibitor optimized to penetrate the blood-brain barrier. A recent study has investigated the activity of lorlatinib against the crizotinib-resistant ROS1G2032R mutation. In this situation, lorlatinib effectively inhibited the catalytic activity of recombinant ROS1G2032R resulting in an antiproliferative response. Because of its potency as an ROS1 inhibitor and its ability to suppress the resistant ROS1 mutations, lorlatinib could be a treatment of choice in ROS1-positive NSCLC.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Centre Hospitalier du Pays d'Aix, Aix-en-Provence, , France
Centre Paul Papin, Angers, , France
Angers - CHU, Angers, , France
Annecy - CH, Annecy, , France
Antony - Hôpital privé, Antony, , France
Avignon - CH, Avignon, , France
Centre Hospitalier de la Côte Basque, Bayonne, , France
Bordeaux - CHU, Bordeaux, , France
Bordeaux - Institut Bergonie, Bordeaux, , France
Bordeaux - Polyclinique, Bordeaux, , France
AP-HP Hôpital Ambroise Paré, Boulogne, , France
Caen - CHU Côte de Nacre, Caen, , France
Chauny - CH, Chauny, , France
Cholet - CH, Cholet, , France
Clermont-Ferrand - CHU, Clermont-Ferrand, , France
Colmar - CH, Colmar, , France
Centre Hospitalier Intercommunal de Créteil, Créteil, , France
Dijon - CRLCC, Dijon, , France
CHRU Grenoble, Grenoble, , France
Centre Hospitalier - Pneumologie, Le Mans, , France
Hôpital Calmette, Lille, , France
Centre Léon Bérard, Lyon, , France
Institut Paoli Calmettes, Marseille, , France
Marseille Hôpital Nord, Marseille, , France
GRH Mulhouse Sud-Alsace, Mulhouse, , France
AP-HP Hôpital Cochin, Paris, , France
AP-HP Hopital Tenon - Pneumologie, Paris, , France
AP-HP Hôpital Bichat, Paris, , France
Paris - Curie, Paris, , France
Lyon - URCOT, Pierre-Bénite, , France
Rouen - CHU, Rouen, , France
Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg, Strasbourg, , France
Hôpital Foch, Suresnes, , France
CHU Toulouse - Pneumologie, Toulouse, , France
CHU Bretonneau, Tours, , France
Valenciennes - Clinique, Valenciennes, , France
Vandoeuvre-lès-Nancy - CHU, Vandœuvre-lès-Nancy, , France
Gustave Roussy, Villejuif, , France
Name: Denis Moro-Sibilot
Affiliation: Grenoble - CHU
Role: STUDY_CHAIR
Name: Michael Duruisseaux
Affiliation: Lyon - URCOT
Role: STUDY_CHAIR